(NASDAQ: SRZN) Surrozen's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.67%.
Surrozen's earnings in 2026 is -$104,844,000.On average, 4 Wall Street analysts forecast SRZN's earnings for 2026 to be -$36,982,253, with the lowest SRZN earnings forecast at -$40,235,964, and the highest SRZN earnings forecast at -$33,029,971. On average, 4 Wall Street analysts forecast SRZN's earnings for 2027 to be -$33,397,685, with the lowest SRZN earnings forecast at -$41,243,964, and the highest SRZN earnings forecast at -$24,569,978.
In 2028, SRZN is forecast to generate -$47,298,815 in earnings, with the lowest earnings forecast at -$45,443,960 and the highest earnings forecast at -$48,689,957.